FDA has granted emergency use authorization to the monoclonal antibody LY-CoV555 (bamlanivimab) from Eli Lilly (NYSE:LLY) to improve the prognosis for recently diagnosed, high-risk COVID-19 patients.  But the investigational medicine must be delivered intravenously. That delivery method is a potential complication as healthcare facilities across the U.S. grapple with a surge of SARS-CoV-2 infections and dwindling ICU…